LEAP-2 Inhibitors
Chemical inhibitors of LEAP-2 can be diverse in their mechanism of action given the multi-faceted nature of the protein's regulation and function. Amiloride, which targets the epithelial sodium channels, can indirectly impede the functionality of LEAP-2 by limiting the availability of these channels that LEAP-2 interacts with. Similarly, Marimastat exerts its inhibitory effect by broadly targeting matrix metalloproteinases, which are involved in the cleavage and subsequent activation of various peptides, including LEAP-2. By impeding this activation process, Marimastat can reduce the biological activity of LEAP-2. Another compound, Chelerythrine, disrupts cellular signaling by inhibiting protein kinase C. This enzyme is crucial for various signaling cascades and can affect the function of peptides like LEAP-2. Therefore, Chelerythrine's action can lead to a decrease in LEAP-2's functional activity by altering its signaling environment.
Continuing along the pathway-centric approach, LY294002 and Wortmannin both target phosphoinositide 3-kinases, pivotal regulators of the AKT signaling pathway. By inhibiting PI3K/AKT signaling, these compounds can downregulate downstream processes that may govern the functional expression of LEAP-2. PD98059 and U0126, as inhibitors of MEK, an integral component of the MAPK/ERK pathway, can decrease LEAP-2 activity by altering intracellular signaling dynamics. SB203580, which inhibits p38 MAPK, and SP600125, a JNK inhibitor, both disrupt specific MAPK pathways. This disruption can lead to a reduced functional state of LEAP-2 through alteration of inflammation and stress response pathways. Rapamycin specifically targets the mTOR pathway, which is involved in fundamental cellular processes that can impact the functionality of LEAP-2. Y-27632, by inhibiting Rho-associated protein kinase, can impact cellular dynamics and, consequently, the activity of LEAP-2. Finally, Go 6983, as a pan-PKC inhibitor, can reduce LEAP-2 activity by modifying the phosphorylation of proteins that are part of cellular signaling pathways where LEAP-2 has a role.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride inhibits epithelial sodium channels (ENaCs). As LEAP-2 is known to interact with these channels, amiloride can indirectly inhibit LEAP-2 by reducing the availability of the channels that LEAP-2 may modulate. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor. By inhibiting MMPs, which are involved in the processing of various peptides, marimastat could impede the cleavage and activation of LEAP-2, thereby functionally inhibiting its activity. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine is a potent inhibitor of protein kinase C (PKC). Since PKC is involved in intracellular signaling and could affect the function of various peptides, inhibiting PKC may lead to a decrease in the functional activity of LEAP-2 by altering its intracellular environment. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. PI3K is involved in the AKT signaling pathway, which can regulate the function of various peptides. Inhibition of this pathway by LY294002 can decrease the functional activity of LEAP-2 by altering downstream signaling events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 may reduce the activity of downstream signaling that could affect the function of LEAP-2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which may decrease the functional activity of LEAP-2 by inhibiting the p38 MAPK signaling pathway, known to be involved in the regulation of inflammatory responses and could indirectly influence LEAP-2 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream in the MAPK/ERK pathway. Inhibition of this pathway with U0126 could reduce the functional activity of LEAP-2 by altering the intracellular signaling environment. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor. By inhibiting PI3K/AKT signaling, Wortmannin can alter the activity of downstream molecules and pathways that could be involved in the functional regulation of LEAP-2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway. mTOR is involved in cell growth, proliferation, and survival. Inhibition of mTOR by rapamycin can decrease the functional activity of LEAP-2 by affecting the cell's regulatory mechanisms. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 can alter the JNK signaling pathway, which could lead to a decrease in the functional activity of LEAP-2 by affecting its regulatory environment. | ||||||